5 Result(s)
-
Article
Open AccessPhase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documente...
-
Article
Open AccessA COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral proteins1,2, combined with the Toll-...
-
Article
Open AccessCD105 (Endoglin) as negative prognostic factor in AML
While several genetic and morphological markers are established and serve to guide therapy of acute myeloid leukaemia (AML), there is still profound need to identify additional markers to better stratify patie...
-
Article
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Patients with acute myeloid leukaemia (AML) often achieve remission after therapy, but subsequently die of relapse1 that is driven by chemotherapy-resistant leukaemic stem cells (LSCs)2,3. LSCs are defined by the...
